A20 (TNFAIP3) Deletion in Epstein-Barr Virus-Associated Lymphoproliferative Disorders/Lymphomas

• Midori Ando,

  Affiliation Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

  ⨯
• Yasuharu Sato ,

  * E-mail: satou-y@cc.okayama-u.ac.jp

  Affiliation Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

  ⨯
• Katsuyoshi Takata,

  Affiliation Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

  ⨯
• Junko Nomoto,

  Affiliation Hematology Division, National Cancer Center Hospital, Tokyo, Japan

  ⨯
• Shigeo Nakamura,

  Affiliation Department of Pathology and Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan

  ⨯
• Koichi Ohshima,

  Affiliation Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan

  ⨯
• Tamotsu Takeuchi,

  Affiliation Department of Immunopathology, Gifu University Graduate School of Medicine, Gifu, Japan

  ⨯
• Yorihisa Orita,

  Affiliation Department of Otolaryngology, Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama, Japan

  ⨯
• Yukio Kobayashi,

  Affiliation Hematology Division, National Cancer Center Hospital, Tokyo, Japan

  ⨯
• Tadashi Yoshino

  Affiliation Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

  ⨯